newsfilter
← Earnings
Earnings Releases·

Interpace Biosciences — Third Quarter 2026 Earnings Summary

  • Q3 2026 revenue rose 18% year-over-year to $10.4 million, while Adjusted EBITDA increased 62% to $2.1 million (20% margin), driven by gross margin expansion to 69%.
  • The company operates exclusively on a thyroid-only basis following the May 2025 discontinuation of PancraGEN, with Q3 thyroid test volumes up 7% and revenue up 18%.
  • Management expects continued margin expansion through operating leverage without headcount increases, though the new pancreatic cancer program is not expected to generate revenue in 2026 or 2027.
  • The balance sheet remains debt-free with $2.929 million in cash as of September 30, 2026, supporting investments in automation, AI, and R&D.
  • Reported GAAP results reflect $4.1 million in non-recurring stock compensation and legal expenses in Q3, which are excluded from Adjusted EBITDA calculations.
Company
INTERPACE BIOSCIENCES INC
Sector
Healthcare
Industry
Diagnostics & Research